FindTrial
Sign In

To assess the body resistance improvement and to evaluate the clinical use and well-being of DailyTabâ?¢Gold immuno booster and DailyTabâ?¢Gold immuno booster (For cardiac, diabetic and neuro conditions) along with standard of care in novel corona virus (COVID-19) patients.

A double blind, placebo controlled, three arm, randomized clinical trial to evaluate the immuno boosting activity and to assess the efficacy and safety of the test products DailyTabâ?¢Gold Immuno Booster and DailyTabâ?¢Gold Immuno Booster (cardiac, diabetic and neuro conditions) Mfd. By LIFECARE NEURO PRODUCTS LTD, Himachal Pradesh (India) along with standard of care in novel corona virus (COVID-19) patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/030165
Enrollment
45
Registered
2020-12-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: DailyTabâ?¢Gold immuno booster along with standard of care: DailyTabâ?¢Gold immuno booster, Oral, One tablet daily after break-fast or lunch for 28 days. Standard of care as per hospita

Sponsors

LIFECARE NEURO PRODUCTS LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Either male or female of age range 18-65 years 2. Patients with mild to moderate COVID-19 infection and RT-PCR confirmed diagnosis of COVID-19. 3. Subjects willing to give written informed consent and come for a regular follow up. 4. Subjects willing to abide by and comply with the study protocol.

Exclusion criteria

Exclusion criteria: 1. Patients presenting severe multisystemic symptoms compatible with advanced Covid-19 and intercurrent acute or severe chronic diseases (i.e. active cancer). 2. Presence of acute hypoxic respiratory failure 3. Requires Intensive care unit (ICU) care for management of ongoing clinical status 4. Severe infection, defined as need for invasive or non-invasive ventilator support 5. Inability to intake or tolerate oral medication 6. Category 6 or 5 based on modified 7-category ordinal scale of clinical status 7. Clinical prognostic non-survival, palliative care, and have no response to supportive treatment within three hours of admission 8. Pregnant or lactating subjects 9. With any secondary complication such as diabetes, cancer, HIV or hypertension.

Design outcomes

Primary

MeasureTime frame
Changes in clinical cure based on clinicianâ??s global assessment of symptomsTimepoint: Day 1, Day 7, Day 14 and Day 28—

Secondary

MeasureTime frame
Changes in C-Reactive Protein & IL-6Timepoint: Baseline and Day 28;Changes in chest X-ray and ECG testsTimepoint: Baseline and Day 28;Changes in Hematology, Biochemistry and urine analysis valuesTimepoint: Baseline and Day 28;Changes in RT-PCR test results from baselineTimepoint: Day 1 and Day 28;Disappearance of symptoms in timeTimepoint: Day 1 to Day 28;Improvement in Oxygen saturation levelsTimepoint: Day 1, Day 7, Day 14 and Day 28;Necessity of invasive assisted ventilation, Necessity of non-invasive assisted ventilation, Intensive care unit admissionTimepoint: Day 1 to Day 28;Post-anesthesia care unit admission, Hospital admission, Medical consultation, Home care and isolation time, Bed rest time etc.Timepoint: Day 1 to Day 28;Subject global assessment of symptomsTimepoint: Day 1 to Day 28;Subjective perception of recoveryTimepoint: Day 28;WHO Covid19 7 point ordinal scale assessmentTimepoint: Day 1, Day 7, Day 14 and Day 28—

Countries

India

Contacts

Public ContactDr Vijender Singh Beniwal

Pharexcel Consulting

info@pharexcelconsulting.com9878551428

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026